Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Balazs Halmos

Showing results (91-100 of 221) with videos related to

Pageof 23
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 19, 2005
Uncommon presentations of some common malignancies: Case 1. Sequential paraneoplastic endocrine syndromes in small-cell lung cancerStephen Mayer, Aaron M Cypess, Olivier N Kocher, et al.
International Journal of Radiation Oncology, Biology, Physics|January 10, 2017
<sup>18</sup>F-Fluorodeoxyglucose/Positron Emission Tomography Predicts Patterns of Failure After Definitive Chemoradiation Therapy for Locally Advanced Non-Small Cell Lung CancerNitin Ohri, William R Bodner, Balazs Halmos, et al.
Investigational New Drugs|April 5, 2013
A Phase I study of the combination of oxaliplatin/docetaxel and vandetanib for the treatment of advanced gastroesophageal cancerBalazs Halmos, Yuxia Jia, Joseph A Bokar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 28, 2018
Wide Expression and Significance of Alternative Immune Checkpoint Molecules, B7x and HHLA2, in PD-L1-Negative Human Lung CancersHaiying Cheng, Alain Borczuk, Murali Janakiram, et al.
Clinical Lung Cancer|August 18, 2019
Survival Disparities in Black Patients With EGFR-mutated Non-small-cell Lung CancerHaiying Cheng, H Dean Hosgood, Lei Deng, et al.
Cancer Research|January 26, 2022
Functional Analysis of MET Exon 14 Skipping Alteration in Cancer Invasion and Metastatic DisseminationFeng Wang, Yang Liu, Wanglong Qiu, et al.
Lung Cancer (Amsterdam, Netherlands)|June 13, 2006
C/EBP alpha mutations in lung cancerDaniel B Costa, Tajhal Dayaram, Francesco D'Alo, et al.
Journal of the American Academy of Dermatology|November 16, 2024
Cutaneous adverse events of osimertinib in diverse patient populations with epidermal growth factor receptor-mutated non-small cell lung cancer: A retrospective cohort analysisDaniel S Alicea, Emily Miao, Peter Ch'en, et al.
Translational Lung Cancer Research|March 14, 2022
Neoadjuvant immunotherapy or chemoimmunotherapy in non-small cell lung cancer: a systematic review and meta-analysisJuan Jiang, Yuling Wang, Yang Gao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 17, 2025
Editor's Note: HHLA2, a New Immune Checkpoint Member of the B7 Family, Is Widely Expressed in Human Lung Cancer and Associated with EGFR Mutational StatusHaiying Cheng, Murali Janakiram, Alain Borczuk, et al.
Pageof 23

Showing results (91-100 of 221) with videos related to

Sort By:
Pageof 23
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 19, 2005
Uncommon presentations of some common malignancies: Case 1. Sequential paraneoplastic endocrine syndromes in small-cell lung cancerStephen Mayer, Aaron M Cypess, Olivier N Kocher, et al.
International Journal of Radiation Oncology, Biology, Physics|January 10, 2017
<sup>18</sup>F-Fluorodeoxyglucose/Positron Emission Tomography Predicts Patterns of Failure After Definitive Chemoradiation Therapy for Locally Advanced Non-Small Cell Lung CancerNitin Ohri, William R Bodner, Balazs Halmos, et al.
Investigational New Drugs|April 5, 2013
A Phase I study of the combination of oxaliplatin/docetaxel and vandetanib for the treatment of advanced gastroesophageal cancerBalazs Halmos, Yuxia Jia, Joseph A Bokar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 28, 2018
Wide Expression and Significance of Alternative Immune Checkpoint Molecules, B7x and HHLA2, in PD-L1-Negative Human Lung CancersHaiying Cheng, Alain Borczuk, Murali Janakiram, et al.
Clinical Lung Cancer|August 18, 2019
Survival Disparities in Black Patients With EGFR-mutated Non-small-cell Lung CancerHaiying Cheng, H Dean Hosgood, Lei Deng, et al.
Cancer Research|January 26, 2022
Functional Analysis of MET Exon 14 Skipping Alteration in Cancer Invasion and Metastatic DisseminationFeng Wang, Yang Liu, Wanglong Qiu, et al.
Lung Cancer (Amsterdam, Netherlands)|June 13, 2006
C/EBP alpha mutations in lung cancerDaniel B Costa, Tajhal Dayaram, Francesco D'Alo, et al.
Journal of the American Academy of Dermatology|November 16, 2024
Cutaneous adverse events of osimertinib in diverse patient populations with epidermal growth factor receptor-mutated non-small cell lung cancer: A retrospective cohort analysisDaniel S Alicea, Emily Miao, Peter Ch'en, et al.
Translational Lung Cancer Research|March 14, 2022
Neoadjuvant immunotherapy or chemoimmunotherapy in non-small cell lung cancer: a systematic review and meta-analysisJuan Jiang, Yuling Wang, Yang Gao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 17, 2025
Editor's Note: HHLA2, a New Immune Checkpoint Member of the B7 Family, Is Widely Expressed in Human Lung Cancer and Associated with EGFR Mutational StatusHaiying Cheng, Murali Janakiram, Alain Borczuk, et al.
Pageof 23